| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6310094 | BAXTER HLTHCARE | Ready-to-use esmolol solution |
Jan, 2021
(3 years ago) | |
| US6528540 | BAXTER HLTHCARE | Esmolol formulation |
Jan, 2021
(3 years ago) | |
|
US6310094 (Pediatric) | BAXTER HLTHCARE | Ready-to-use esmolol solution |
Jul, 2021
(2 years ago) | |
|
US6528540 (Pediatric) | BAXTER HLTHCARE | Esmolol formulation |
Jul, 2021
(2 years ago) | |
Brevibloc is owned by Baxter Hlthcare.
Brevibloc contains Esmolol Hydrochloride.
Brevibloc has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Brevibloc are:
- US6310094
- US6528540
- US6310094*PED
- US6528540*PED
Brevibloc was authorised for market use on 15 August, 1988.
Brevibloc is available in injectable;injection dosage forms.
The generics of Brevibloc are possible to be released after 12 July, 2021.
Drugs and Companies using ESMOLOL HYDROCHLORIDE ingredient
Market Authorisation Date: 15 August, 1988
Treatment: NA
Dosage: INJECTABLE;INJECTION
How can I launch a generic of BREVIBLOC before it's drug patent expiration?
More Information on Dosage
BREVIBLOC family patents
